HPV16陽性頭頸部扁平上皮がん市場は2034年まで9.2%のCAGRで大幅な成長が見込まれる | DelveInsight

The HPV16+ HNSCC market is witnessing strong expansion, propelled by growing recognition of HPV-associated cancers and a rising number of oropharyngeal cancer cases. The advancement of immunotherapy-based approaches and targeted treatments, particularly immune checkpoint inhibitors, is accelerating market development. Improvements in diagnostic methods and individualized treatment strategies are also enhancing patient outcomes and supporting the market's continued growth.

DelveInsight's report on HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Insights offers a thorough overview of existing treatment approaches, emerging HPV16+ HNSCC therapies, individual therapy market shares, and historical and projected market size spanning 2020 to 2034 across the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Highlights from the HPV16-Positive HNSCC Market Report

• DelveInsight's analysis indicates that the HPV16+ HNSCC market was valued at roughly USD 750 million across the 7MM in 2023.
• Within the US, the oropharynx accounted for the largest share of site-specific HNSCC cases in 2023.
• DelveInsight estimates that the total number of new HPV16+ HNSCC cases across the 7MM reached approximately 45,000 in 2023.
• The surge in HPV-positive HNSCC cases is not anticipated to peak until the 2030s, owing to the delayed uptake of preventive vaccination among younger populations. Moreover, since older demographics remain largely unvaccinated, immunization efforts are unlikely to meaningfully reduce HPV16-positive oropharyngeal squamous cell carcinoma (OPSCC) prevalence until after 2045. Until vaccination coverage achieves full penetration, the population at risk of disease progression despite curative treatments continues to expand — even as more patients have a chance of being cured. This underscores a pressing need for better therapeutic options.
• Prominent companies advancing emerging HPV16+ HNSCC treatments include Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, and others — all working on novel drugs poised to enter the market in the coming years.
• Notable pipeline therapies include Petosemtamab (MCLA-158), Zanzalintinib, ISA101b, Versamune HPV (formerly PDS0101), BNT113, CUE-101, Eftilagimod alpha (Efti/IMP321), INO-3112 (MEDI0457), VB10.16 (VB-C-03), Tivumecirnon (FLX475), SCG142, and others.
• In February 2025, the US FDA granted Breakthrough Therapy designation (BTD) to Merus' petosemtamab combined with pembrolizumab for first-line treatment of adult patients with recurrent or metastatic PD-L1-positive HNSCC (CPS ≥ 1). This marks petosemtamab's second BTD, following the first BTD and Fast Track designations awarded in May 2024 and August 2023, respectively, for patients with recurrent and/or metastatic HNSCC progressing after platinum-based chemotherapy and anti-PD-1 therapy.
• Also in February 2025, PDS Biotechnology confirmed the initiation of its VERSATILE-003 Phase III clinical trial evaluating Versamune HPV plus KEYTRUDA in Q1 2025 as a frontline therapy for recurrent and/or metastatic HPV16-positive HNSCC.
• In October 2024, Exelixis established a clinical development partnership to assess the combination of zanzalintinib with KEYTRUDA in a Phase III pivotal study for HNSCC patients.
• The demonstrated effectiveness of immune checkpoint inhibitors in recurrent and metastatic HNSCC has generated increasing interest in their neoadjuvant application. Neoadjuvant immunotherapy holds promise for HNSCC, as it may lower the risk of local recurrence and distant spread, potentially improving long-term survival.

👉 Discover which therapies are expected to capture the largest HPV16+ HNSCC market share @ HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Report

HPV16-Positive Head and Neck Squamous Cell Carcinoma Overview

HPV16-positive head and neck squamous cell carcinoma (HPV16+ HNSCC) is a malignancy originating in the mucosal lining of the oropharynx, driven by persistent HPV16 infection. In contrast to conventional HNSCC, which is closely associated with tobacco and alcohol consumption, HPV16+ HNSCC is predominantly caused by high-risk HPV infection, frequently transmitted through oral sexual contact.

Common symptoms include a persistent sore throat, difficulty swallowing, voice changes, ear pain, swollen lymph nodes, and unexplained weight loss. This cancer type typically presents with relatively small primary tumors but notable lymph node involvement. Diagnosis relies on physical examination, imaging studies (CT, MRI, or PET scans), and tissue biopsy. HPV status is verified using polymerase chain reaction (PCR) or in situ hybridization (ISH) to identify viral DNA, while p16 immunohistochemistry (IHC) serves as a surrogate indicator of HPV-driven disease. Compared to HPV-negative HNSCC, HPV16+ HNSCC generally has a more favorable prognosis and better treatment response, making precise diagnosis essential for guiding therapeutic decisions.

HPV16+ HNSCC Epidemiology Breakdown

The epidemiology section of the report provides an overview of historical and current HPV16+ HNSCC patient populations along with projected trends across the 7MM. It identifies the factors behind observed and anticipated patient trends by analyzing multiple studies and expert perspectives.

The epidemiological analysis covers 2020–2034 across the 7MM, segmented by:

• Total new cases of head and neck cancer
• Total new cases of HNSCC
• Site-specific HNSCC cases
• Total new HPV+ HNSCC cases
• Total new HPV16+ HNSCC cases
• Stage-specific HPV16+ OPSCC cases
• Stage-specific HPV16+ non-OPSCC cases]

HPV16-Positive HNSCC Treatment Landscape

Standard treatment for locoregionally advanced HPV16+ HNSCC typically involves chemoradiation (CRT) or surgery followed by adjuvant therapy. However, recurrence and metastasis rates remain elevated, particularly in advanced stages. KEYTRUDA and OPDIVO are the principal PD-1 inhibitors approved for treating recurrent or metastatic HNSCC.

OPDIVO (nivolumab) – Bristol Myers Squibb:

• November 2016: US FDA approval for recurrent or metastatic SCCHN patients with disease progression following platinum-based therapy.
• April 2017: European Commission approval as monotherapy for adults with SCCHN progressing on or after platinum-based treatment.
• 2021: UK NICE recommendation for recurrent or metastatic HNSCC patients who progressed during or after platinum-based chemotherapy.
• March 2017: Japanese approval for relapsed or distant metastatic head and neck cancer.
• April 2016: US FDA Breakthrough Therapy Designation for recurrent or metastatic SCCHN following platinum-based therapy.

KEYTRUDA (pembrolizumab) – Merck:

• June 2019: US FDA approval as first-line treatment for metastatic or unresectable recurrent HNSCC, including HPV-positive patients.
• August 2016: Accelerated US FDA approval for recurrent or metastatic HNSCC with disease progression after platinum-based chemotherapy, including HPV-positive patients.
• November 2019: European Commission approval as first-line treatment for metastatic or unresectable recurrent HNSCC with PD-L1 expression (CPS ≥ 1).
• December 2019: Japanese PMDA approval as both combination therapy and monotherapy for first-line treatment of recurrent or metastatic head and neck cancer.

KEYTRUDA monotherapy remains the recommended first-line option for recurrent or metastatic HNSCC with high PD-L1 expression, although only approximately 20% of patients respond, and HPV status does not substantially influence response rates. Notably, no treatments currently hold specific approval for HPV16+ cancers.

👉 To learn more about HPV16+ HNSCC treatment guidelines, visit @ HPV16-Positive Head and Neck Squamous Cell Carcinoma Management

HPV16+ HNSCC Pipeline Treatments and Key Developers

👉 Discover more about HPV16+ HNSCC drugs in development @ HPV16+ HNSCC Clinical Trials

HPV16+ HNSCC Market Dynamics

The HPV16+ HNSCC market is expected to undergo considerable transformation in the years ahead. The growing incidence of HPV-associated cancers, particularly HPV16+ HNSCC, is increasing demand for targeted therapies and preventive vaccines. Heightened awareness of the connection between HPV16 and HNSCC is driving greater emphasis on early detection and prevention strategies, including expanded vaccination programs. The creation of novel immunotherapies and treatments designed specifically for HPV16+ cancers represents a key growth driver, offering enhanced efficacy compared to traditional chemotherapy and radiation.

The rising prevalence of HPV infections, especially among younger populations, is also motivating healthcare providers and researchers to invest in improved screening technologies and treatment modalities. Governmental support, regulatory approvals, and increased oncology healthcare spending further bolster market growth, opening doors for innovative therapies in this rapidly evolving field.

The competitive landscape features major players such as PDS Biotechnology, ISA Pharmaceuticals, Immutep, BioNTech, Cue Pharma, and others pursuing innovative approaches to enhance treatment efficacy and broaden options for HPV16+ HNSCC patients who currently have limited alternatives.

Multiple potential therapies under investigation for HPV16+ HNSCC are expected to meaningfully shape the treatment landscape during the forecast period. The anticipated launch of emerging therapies with superior efficacy, coupled with improvements in diagnostic rates, is projected to drive substantial market growth across the 7MM.

Several HPV-targeted therapeutic vaccines for HNSCC are currently under study, with the most promising results emerging from combinations with checkpoint inhibitors in first-line recurrent or metastatic settings. While some trials are examining these vaccines in treatment-refractory patients, response rates in that population tend to be more modest. Investigations into standalone therapeutic vaccines without immunotherapy are also underway.

Market Challenges:

Several factors could constrain HPV16+ HNSCC market growth. The complex and heterogeneous nature of HNSCC poses difficulties in developing universally effective targeted therapies. Limited widespread screening leads to late-stage diagnoses, diminishing treatment effectiveness. Regulatory obstacles, including prolonged clinical trial requirements and rigorous safety evaluations, present additional barriers.

HPV16+ HNSCC treatment also imposes a substantial economic burden and adversely affects patients' quality of life. Market growth could be further tempered by clinical trial failures, therapy discontinuations, prohibitive pricing, reimbursement challenges, and shortages of specialized healthcare professionals. Undiagnosed and unreported cases, along with insufficient disease awareness, may also limit market expansion.

Market Report Summary

Report Scope

• Therapeutic Assessment: Current marketed and emerging HPV16+ HNSCC therapies
• Market Dynamics: Key forecast assumptions for emerging drugs and market outlook
• Competitive Intelligence: SWOT analysis and market entry strategies
• Additional Coverage: Unmet needs, KOL perspectives, analyst insights, market access and reimbursement analysis

👉 Download the report to understand which factors are driving HPV16+ HNSCC market trends @ HPV16+ HNSCC Market Trends

Table of Contents

Related Reports

HPV16+ Cancers Market This report provides an in-depth examination of the disease, historical and projected epidemiology, market trends, drivers, barriers, and key companies including GlaxoSmithKline, PDS Biotechnology, Merck, Cue Biopharma, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Vaccibody AS, Transgene, Inovio Pharma, Hookipa Pharma, Roche Pharma AG, Invectys, BioNTech, Advaxis Inc., Precigen, and others.

Head and Neck Squamous Cell Carcinoma Market This report delivers comprehensive insights into the disease, epidemiological data, market trends, and key companies such as VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals, and others.

Recurrent Head and Neck Squamous Cell Carcinoma Pipeline This pipeline insight report offers thorough coverage of the therapeutic landscape, drug profiles across clinical and preclinical stages, and key companies including AstraZeneca, Astellas, GlaxoSmithKline, Boehringer Ingelheim, Merck, and others.

Human Papillomavirus Market This report covers disease understanding, epidemiological analysis, market trends, and key companies including Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, and others.

About DelveInsight

DelveInsight is a premier business consulting and market research firm dedicated exclusively to the life sciences sector. The company assists pharmaceutical organizations by delivering comprehensive, end-to-end solutions designed to enhance their performance. Seamless access to all healthcare and pharma market research reports is available through DelveInsight's subscription-based platform, PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/